The Discern test provides definitive diagnosis of AD as against other forms of dementia. Credit: Steve Buissinne / Pixabay.

Synaps Dx has announced that its Discern test for Alzheimer’s disease (AD) has received proprietary laboratory analyses (PLA) Code 206U and 207U.

This code set is approved by the American Medical Association Current Procedural Terminology (CPT) Editorial Panel.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Discern test is an autopsy-validated, minimally invasive test designed to enable definitive diagnosis of AD as against other forms of dementia in a patient. It uses a small skin sample of the patient to provide clinicians with a diagnosis that has a 95% certainty.

Discern is claimed to be the first AD test of its kind to obtain PLA Code 206U and 207U.

The PLA codes are alpha-numeric CPT codes that are provided with a corresponding descriptor for labs or manufacturers looking to identify their test more specifically.

Synaps Dx CEO and president Frank Amato said: “With a growing number of payers looking at the cost and effectiveness of new drugs and therapies for AD, as well as indicators of early-stage AD and benchmarks for coverage decisions, PLA codes distinguish the market position of Discern and impact reimbursement.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Discern is now positioned as a critical, essential component of patient-centric, value-based strategies for providers and payers, with three SDx AD biomarkers that accurately identify and distinguish AD from all other dementias.

“Appropriate medical coding ensures that insurers have all the diagnostic codes necessary for payment.”

The US sees 500,000 new cases of dementia each year. Around two million patients are in the first three years of the disease at any given time.

The use of the Discern test is expected to provide early detection of AD in patients and will facilitate subsequent caregiving.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact